
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the month of Dec, 2022

Commission File Number: 001-41106

Incannex Healthcare Limited
(Exact name of Registrant as specified in its charter)

not applicable
(Translation of Registrant's name into English)

Australia
(Jurisdiction of incorporation or organization)

Joel Latham
Chief Executive Officer and Managing Director
Level 39, Rialto South Tower
525 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 01, 2022, Incannex Healthcare Limited filed with the Australian Securities Exchange an announcement captioned "Trading Halt", a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Incannex Healthcare Limited

Date: December 01, 2022

By: /s/ Joel Latham
Name: Joel Latham
Title: Chief Executive Officer and Managing Director

INDEX TO EXHIBITS

Exhibit No.

99.1 [ASX Announcement, dated December 01, 2022 – Trading Halt](#)



Market Announcement

1 December 2022

Incannex Healthcare Limited (ASX: IHL) – Trading Halt

Description

The securities of Incannex Healthcare Limited ('IHL') will be placed in trading halt at the request of IHL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 5 December 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

1 December 2022

ASX Limited

Market Announcement 1/1

ASX Customer Service Centre 131 279 | asx.com.au



Date: 1st December 2022
Public Announcement (NASDAQ: IXHL) (ASX: IHL)

Melissa Kostopoulos
ASX Listings Compliance adviser
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By email: Melissa.Kostopoulos@asx.com.au
tradinghaltsmelbourne@asx.com.au

Dear Melissa,

REQUEST FOR TRADING HALT – INCANNEX HEALTHCARE LIMITED

Incannex Healthcare Limited ('Company') requests a trading halt to be applied to its securities under ASX Listing Rule 17.1 pending an announcement by the Company regarding a strategic institutional capital raising.

The Company requests that the trading halt commences immediately. The Company requests that the trading halt remains in place until the earlier of the commencement of normal trading on 05th December 2022 or the release of the announcement.

The Company confirms that it is not aware of any reason why the trading halt should not be granted or of any information other than that set out above necessary to inform the market about the trading halt.

For and on behalf of the Board of Incannex Healthcare Limited.

Regards,

Madhukar Bhalla
Company Secretary

Incannex Healthcare Limited (ABN: 93 096 635 246)
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC
3000 P: +61 (0) 409 840 786